

1 **CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity** 2 **and death**

3 Yves Lévy^{1,2*}, Aurélie Wiedemann^{1‡}, Boris P. Hejblum^{1,3‡}, Mélanie Durand^{1,3}, Cécile
4 Lefebvre¹, Mathieu Surénaud¹, Christine Lacabaratz¹, Matthieu Perreau⁴, Emile Foucat¹,
5 Marie Déchenaud¹, Pascaline Tisserand¹, Fabiola Blengio¹, Benjamin Hivert³, Marine
6 Gautier³, Minerva Cervantes-Gonzalez^{5,6,7}, Delphine Bachelet^{5,7}, Cédric Laouénan^{5,7}, Lila
7 Bouadma⁸, Jean-François Timsit⁸, Yazdan Yazdanpanah^{6,7}, Giuseppe Pantaleo^{1,4,9}, Hakim
8 Hocini^{1†}, Rodolphe Thiébaud^{1,3,10*†} and the French COVID cohort study group^a

9 *Affiliations*

- 10 1. Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine,
11 INSERM U955, Team 16, Créteil, France.
- 12 2. Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier,
13 Service Immunologie Clinique, Créteil, France
- 14 3. Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
15 Research Centre, Inria SISTM, UMR 1219; Bordeaux, France
- 16 4. Swiss Vaccine Research Institute, Lausanne University Hospital, University of
17 Lausanne, Lausanne, Switzerland
- 18 5. AP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche
19 Clinique, INSERM, Centre d'Investigation clinique-Epidémiologie Clinique 1425
20 F-75018 Paris, France
- 21 6. AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018
22 Paris, France
- 23 7. Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, France
- 24 8. APHP- Hôpital Bichat – Médecine Intensive et Réanimation des Maladies
25 Infectieuses, Paris, France
- 26 9. Immunology and Allergy Service, Department of Medicine; Lausanne University
27 Hospital, University of Lausanne, Lausanne, Switzerland.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 10. CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale,
29 Bordeaux, France

30 ***Correspondence:** Pr. Yves Lévy, Vaccine Research Institute, INSERM U955, Hopital Henri
31 Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France, Phone: +33 (0) 1 49
32 81 44 42, Fax: +33 (0) 1 49 81 24 69, E-mail: yves.levy@aphp.fr & Pr Rodolphe Thiébaud,
33 Université de Bordeaux, INSERM U1219 Bordeaux Population Health, 146 Rue Leo Saignat
34 33076 Bordeaux Cedex, France, Phone : +33 (0) 5 57 57 45 21, Fax : +33 (0) 5 56 24 00 81,
35 E-mail: rodolphe.thiebaut@u-bordeaux.fr

36 ‡these authors contributed equally to this work

37 † co-last authors

38 ^a Members of the French COVID study group are in listed in Supplementary Information

39

40 **Abstract**

41 COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent
42 infection to severe disease and death. The identification of high-risk patients is a continuing
43 challenge in routine care. We aimed to identify factors that influence clinical worsening. We
44 analyzed 52 cell populations, 71 analytes, and RNA-seq gene expression in the blood of
45 severe patients from the French COVID cohort upon hospitalization (n = 61). COVID-19
46 patients showed severe abnormalities of 27 cell populations relative to healthy donors (HDs).
47 Forty-two cytokines, neutrophil chemo-attractants, and inflammatory components were
48 elevated in COVID-19 patients. Supervised gene expression analyses showed differential
49 expression of genes for neutrophil activation, interferon signaling, T- and B-cell receptors, EIF2
50 signaling, and ICOS-ICOSL pathways in COVID-19 patients. Unsupervised analysis confirmed
51 the prominent role of neutrophil activation, with a high abundance of CD177, a specific
52 neutrophil activation marker. CD177 was the most highly differentially-expressed gene
53 contributing to the clustering of severe patients and its abundance correlated with CD177
54 protein serum levels. CD177 levels were higher in COVID-19 patients from both the French
55 and “confirmatory” Swiss cohort (n = 203) than in HDs (P< 0.01) and in ICU than non-ICU
56 patients (P< 0.001), correlating with the time to symptoms onset (P = 0.002). Longitudinal
57 measurements showed sustained levels of serum CD177 to discriminate between patients with
58 the worst prognosis, leading to death, and those who recovered (P = 0.01). These results
59 highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a
60 reliable prognostic marker for routine care.

61

62 Introduction

63 The Coronavirus Disease 2019 (COVID-19) pandemic is caused by a newly described highly
64 pathogenic beta coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-
65 CoV-2) ^{1,2}. COVID-19 consists of a spectrum of clinical symptoms that range from mild upper
66 respiratory tract disease in most cases to severe disease that affects approximately 15% of
67 patients requiring hospitalization ³, some of whom require intensive care because of severe
68 lower respiratory tract illness, acute respiratory distress syndrome (ARDS), and extra-
69 pulmonary manifestations, leading to multi-organ failure and death. Several recent studies
70 have provided important clues about the pathophysiology of COVID-19 ⁴⁻⁸. Most compared
71 the immune and inflammatory status of patients at different stages of the disease ⁹⁻¹¹. Thus,
72 several important biomarkers associated with specific phases of the evolution of COVID-19
73 have thus far been identified ^{12,13}. Inflammation, cytokine storms, and other dysregulated
74 immune responses have been shown to be associated with severe disease pathogenesis
75 ^{14,15}. Severe COVID-19 patients are characterized by elevated numbers of monocytes and
76 neutrophils and lymphopenia ^{10,16-18}, and a high neutrophil to lymphocyte ratio predicts in-
77 hospital mortality of critically-ill patients ¹⁹. High levels of pro-inflammatory cytokines,
78 including IL-6, IL-1 β , TNF, MCP-1, IP-10, and G-CSF, in the plasma ^{5,10,16,18,20} and a possible
79 defect in type I interferon activity have been reported in patients with severe COVID-19 ^{9,15,21}.
80 However, these responses are dynamic, changing rapidly during the clinical course of the
81 disease, which may explain the high variability of the immunological spectrum described
82 ^{14,21,22}. This makes it difficult to deduce a unique profile of the pathophysiology of this
83 infection, which is still undetermined. Furthermore, the high amplitude of the signals
84 generated by the inflammation associated with the disease may hide other pathways that are
85 involved.

86 From a clinical standpoint, clinicians face the daily challenge of predicting worsening patients
87 due to the peculiar clinical course of severe COVID-19, characterized by a sudden
88 deterioration of the clinical condition 7 to 8 days after the onset of symptoms. Determination

89 of the onset of the pathological process once infection has been established in a patient with
90 a severe stage of infection is highly imprecise because of the possible pauci- or
91 asymptomatic phase of the infection, as well as the low specificity of self-limited “flu” illness.

92 We used a systems immunology approach to identify host factors that were significantly
93 associated with the time to illness onset, severity of the disease (ICU or transfer to ICU), and
94 mortality of COVID-19 patients enrolled in the multicentric French COVID cohort ²³. In
95 addition to the depletion of T cells and mobilization of B cells, neutrophil activation, and
96 severe inflammation, we show upregulation of CD177 gene expression and protein levels in
97 the blood of COVID-19 patients in both the COVID-19 cohort and a “confirmatory” cohort,
98 i.e., Swiss cohort, relative to healthy subjects. CD177, a neutrophil activation marker,
99 characterized critically ill patients and marked disease progression and death. Our finding
100 highlights the major role of neutrophil activation through CD177 over-expression in the critical
101 clinical transition point in the trajectory of COVID-19 patients.

102

103

104 **Results**

105 **Overview of the phenotype, cytokine, and inflammatory profiles of COVID-19 patients**

106 Patient characteristics from the French COVID cohort enrolled in this analysis are shown in
107 Table 1. All patients from this cohort were stratified as severe according to criteria of the
108 French COVID cohort (clinicaltrials.gov NCT04262921) ²³, with 53 (87%) hospitalized in an
109 ICU (either initially or after clinical worsening or death) and eight not. The median age was
110 60 years ([interquartile range (IQR)], [50-69]) and 80% were male. Sampling for
111 immunological analyses was performed within three days of entry and after a median of 11
112 days [7-14] after symptoms onset. We first assessed leukocyte profiles by flow cytometry
113 using frozen peripheral blood mononuclear cells (PBMCs) from 50 COVID-19 patients (with
114 available PBMC samples) and 18 healthy donors (HDs) (14 or 15 HDs were used as controls
115 per immune-cell subset).

116 We analyzed 52 immune cell populations, of which 23 showed significant differences
117 (Wilcoxon test adjusted for multiple comparisons) between the COVID-19 patients and HDs.
118 We not only confirmed previously reported abnormalities but also revealed new
119 immunological features of COVID-19 patients (supplementary Figure 1). The COVID-19
120 patients showed a significant reduction in the frequency of total CD3⁺ T cells and CD8⁺ T
121 cells relative to HDs, as previously reported ^{24,25}, that expressed an activated phenotype
122 (CD38⁺HLA-DR⁺) (Figure 1A). The COVID-19 patients also showed lower frequencies of
123 resting memory B cells contrasting with higher frequencies of activated memory B cells and
124 exhausted B cells (Figure 1B). As previously reported ^{10,22}, the proportion of plasmablasts
125 was markedly higher in COVID-19 patients (median [Q1-Q3]: 10.85% [3-23]) than HDs
126 (0.76% [0.4-0.8]) (P < 0.001). Total NK-cell frequencies, more precisely those of the
127 CD56^{bright} and CD56^{dim}CD57⁻ NK-cell subpopulations, were lower than in HDs (P = 0.017, P <
128 0.001, and P = 0.004, respectively) (Figure 1C), while a higher proportion of these NK cells,
129 as well as NKT cells, were cycling, expressing Ki67 antigen (CD56^{bright}: 22% [13-30],
130 CD56^{dim}CD57⁻: 16.8% [11.5-27], and NKT: 10% [5.6-18.2]) (P = 0.003, P = 0.004, and P =

131 0.001 compared to HD) (Figure 1C). In addition, COVID 19-patients showed significantly
132 smaller classical (CD14⁺CD16⁻), intermediate (CD14⁺CD16⁺), and non-classical (CD14⁻
133 CD16⁺) monocyte subpopulations than HDs (P = 0.013, P = 0.017, P < 0.001, respectively)
134 (Figure 1D). Interestingly, COVID-19 patients tended to exhibit a higher frequency of $\gamma\delta$ T
135 cells than HDs (median 10.4% [7.5-16.1] vs 7.3% [6-10] in HDs; P = 0.068) (Figure 1E), with
136 a significant proportion of $\gamma\delta$ T cells showing higher expression of the activation marker
137 CD16 (P = 0.01) and lower expression of the inhibitory receptor NKG2A (P < 0.001) than
138 HDs (Figure 1E). Finally, we observed markedly smaller frequencies of dendritic cells (DCs)
139 for all populations studied (pre-DC, plasmacytoid DC (pDC), and conventional DC (cDC1 and
140 cDC2) in COVID-19 patients than in HDs (P < 0.001, for all comparisons) (Figure 1F).

141 We then evaluated the levels of 71 serum cytokines, chemokines, and inflammatory factors
142 in 33 COVID-19 patients and 5 HDs. Forty-four analytes differed significantly (Wilcoxon test
143 adjusted for multiple comparisons) between the COVID-19 patients and HDs (shown in the
144 heatmap in Figure 2 and detailed in Supplementary Figure 2). The levels of 42 factors were
145 higher, among them, pro-inflammatory factors (IL-1a, IL-6, IL-18, tumor necrosis factor- α and
146 β (TNF- α , TNF- β), IL-1ra, ST2/IL-1R4, the acute phase protein lipopolysaccharide binding
147 protein LBP, IFN- α 2); Th1 pathway factors (IL-12 (p70), IFN- γ , IP-10, IL-2Ra); Th2/regulatory
148 cytokines (IL-4, IL-10, IL-13); IL-17, which also promotes granulocyte-colony stimulating
149 factor (G-CSF)-mediated granulopoiesis and recruits neutrophils to inflammatory sites; T-cell
150 proliferation and activation factors (IL-7, IL-15); growth factors (SCF, SCGF-b, HGF, b-FGF,
151 b-NGF); and a significant number of cytokines and chemokines involved in macrophage and
152 neutrophil activation and chemotaxis (RANTES (CCL5), MIP-1a and b (CCL3 and CCL4),
153 MCP-1 (CCL2), MCP-3 (CCL7), M-CSF, MIF, Gro-a (CXCL1), monokine inducible by γ
154 interferon MIG/CXCL9, IL-8, IL-9). Interestingly, we found higher levels of midkine, a marker
155 usually not detectable in the serum, which enhances the recruitment and migration of
156 inflammatory cells and contributes to tissue damage ²⁶. In parallel, Granzyme B and IL-21

157 levels were significantly lower in COVID-19 patients than HDs ($P = 0.007$ and $P = 0.004$,
158 respectively) (Supplementary Figure 2).

159 **Whole blood gene expression profiles show a specific signature for COVID-19 patients**

160 The comparison of gene abundance in whole blood between COVID-19 patients ($n = 44$) and
161 HDs ($n = 10$) showed 4,079 differentially expressed genes (DEG) with an absolute fold
162 change ≥ 1.5 , including 1,904 that were upregulated and 2,175 that were downregulated
163 (Figure 3A). The main pathways associated with the DEG correspond to the immune
164 response, including neutrophil and interferon signaling, T and B cell receptor responses,
165 metabolism, protein synthesis, and regulators of the Eif2 and mammalian target of
166 rapamycin (mTOR) signaling pathways (Figure 3A). Although several of these pathways
167 involved multiple cell types, analysis of the neutrophil pathway showed higher abundance of
168 genes mainly related to neutrophil activation, their interaction with endothelial cells, and
169 migration (Figure 3B). Among the most highly expressed genes, this signature included
170 CD177, a specific marker of neutrophil adhesion to the endothelium and transmigration ²⁷,
171 HP (Haptoglobin), a marker of granulocyte differentiation and released by neutrophils in
172 response to activation ²⁸, VNN1 (hematopoietic cell trafficking), GPR84 (neutrophil
173 chemotaxis), MMP9 (neutrophil activation and migration), and S100A8 and S100A12
174 (neutrophil recruitment, chemotaxis, and migration). The S100A12 protein is produced
175 predominantly by neutrophils and is involved in inflammation and the upregulation of vascular
176 endothelial cell adhesion molecules ²⁹ (Figure 3B).

177 In parallel, we observed a higher abundance of several interferon stimulating genes (ISG)
178 (IFI27, IFITM3, IFITM1, IFITM2, IFI6, IRF7, IRF4) (Figure 3C) and cytokines and cytokine
179 receptors (IL-1R, IL-18R1, IL-18RAP, IL-4R, IL-17R, IL-10) (Figure 3D). Consistent with
180 profound T-cell lymphopenia, the expression of several families of T-cell Receptor (TCRA)
181 genes was lower (Figure 3E). We observed severe dysregulation of T-cell function that
182 involved inhibition of serine/threonine kinase PKC θ signaling (z-score = -4.46) (data not
183 shown), as well as the inducible T-cell co-stimulator/ICOSL axis (z-score = -4.5)

184 (Supplementary Figure 3). In contrast to the results for T cells, the peripheral expansion of
185 memory B cells and plasmablasts was associated with broad expansion of the B-Cell
186 Receptor (BCR) (Figure 3F and Supplementary Table 2).

187 We also observed genes belonging to several crucial pathways and biological processes that
188 had not been previously reported to characterize COVID-19 patients to be underrepresented.
189 These included EIF2 signaling, with many downregulated genes, such as ribosomal proteins
190 (RP) and eukaryotic translation initiation factors (EIFs) (Supplementary Figure 3A), common
191 targets of the integrated stress response (ISR), including antiviral defense^{30,31}. In addition,
192 we also found genes involved in signaling through mTOR (supplementary Figure 3B), a
193 member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases.
194 Prediction analysis using Ingenuity pathways showed both lower EIF2 (z-score = - 6.8) and
195 mTOR (z-score = -2.2) signaling in COVID-19 patients than HDs.

196 **Unsupervised whole blood gene expression profiles reveal distinct features of COVID-** 197 **19 patients.**

198 Unsupervised classification of 44 COVID-19 patients and 10 HDs identified three distinct
199 groups of COVID-19 patients: 10 in group 1, 16 in group 2, and 18 in group 3 (Figure 4).
200 Detailed patient characteristics according to group are presented in supplementary Table 1.
201 Among a large set of clinical and biological characteristics, the analysis showed the
202 differential clustering to not be explained by the severity of the disease. Indeed, the median
203 Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology Score
204 (SAPS2), which include a large number of physiological variables^{32,33} and evaluate the
205 clinical severity of the disease (a high score is associated with a worse prognosis) of the
206 COVID-19 patients, were 6 [4-7] and 36 [28-53], respectively, with no significant differences
207 between groups. Nevertheless, we observed a significant difference in the median time to
208 symptoms onset at admission, which ranged from 7 [6 –11] days for patients in group 1 to 11
209 [10-14] and 13 [9-14] days for patients in groups 2 and 3, respectively (P = 0.04, Kruskal-

210 Wallis test). Finally, group 1 which was the closest to HDs in terms of gene profile, consisted
211 of patients in the early days of the disease (Supplementary Table 1).

212 Analysis of the genes contributing to the differences between groups confirmed and
213 extended the findings described above (Figure 3 and Supplementary Figure 3). Several
214 pathways were highly represented in sectors of the heatmap defined according to gene
215 abundance across patient groups. For example, 97% of the genes making up the BCR and
216 65% of those involved in neutrophil responses were represented among the genes showing
217 a greater abundance in COVID-19 groups 2 and 3 than group 1 and HDs (Figure 4). Other
218 pathways, such as those for interferon (64%), TCR (100%), iCOS-iCOS-L (88%), mTOR
219 (81%), and Eif2 signaling (92%) were also highly represented. The interferon signaling
220 genes, such as IFI44L, IFIT2, and IRF8, a regulator of type I Interferon (α , β), were
221 significantly more abundant at earlier stages (in patients from group 2) and tended to be less
222 abundant in group 3, at more advanced stages of the disease. Finally, the abundance of
223 genes belonging to T-cell pathways (TCR, iCOS-iCOSL signaling) or mTOR and EIF2
224 signaling was lower in group 3, that is to say, those who were analyzed after a longer time to
225 symptoms onset. The findings described above highlight the heterogeneity of COVID-19
226 patients.

227 **Integrative analysis of all biomarkers reveals the major contribution of CD177 in the** 228 **clinical outcome of COVID-19 patients.**

229 We performed an integrative analysis using all available data to disentangle the relative
230 contribution of the various markers at the scale of every patient. We thus pooled the data for
231 29,302 genes from whole blood RNA-seq, cell phenotypes (52 types), and cytokines (71
232 analytes) using the recently described MOFA approach³⁴, which is a statistical framework for
233 dimension reduction adapted to the multi-omics context. The data are reduced to
234 components that are linear combinations of variables explaining inter-patient variability
235 across the three biological measurement modalities. The first component, that we called our
236 integrative score, discriminated between the three groups of COVID-19 patients and HDs

237 (Figure 5A), although it only explained a portion of the variability within each of the three
238 types of markers (14% of gene expression, 14% of cell phenotypes, and 5% of cytokines).
239 The main contributors for the cell phenotype were the significantly lower frequency of cDC2
240 and T cells and, marginally, the higher number of plasmablasts and CD16⁺ $\gamma\delta$ T cells in
241 COVID-19 patients (Figure 5B). The contribution of soluble factors was marked by higher
242 levels of soluble CD163 (sCD163), a marker of polarized M2 macrophages involved in tissue
243 repair ³⁵, in more advanced COVID-19 groups (Figure 5C). Indeed, CD163 gene expression
244 was also significantly higher in COVID-19 patients than HDs (log₂ fold change = +1.55; FDR
245 = 4.79 10⁻²). sCD163 has also been reported to be a marker of disease severity in critically ill
246 patients with various inflammatory or infectious conditions ³⁶. Interestingly, the genes that
247 contribute the most to the synthesis of this factor were part of the neutrophil module (CD177,
248 ARG1, MMP9) (Figure 5D). The increasing abundance of CD177 gene expression according
249 to group was again clearly apparent (Supplementary Figure 4). Integrated analysis also
250 revealed higher expression of proprotein convertase subtilisin/kexin type 9 (PCSK9). High
251 plasma PCSK9 levels highly correlate with the development and aggravation of subsequent
252 multiple organ failure during sepsis ^{37,38}. Of note, high PCSK9 levels have been recently
253 associated with severe Dengue infection ³⁹.

254 **Serum CD177 protein levels are associated with the clinical outcome of COVID-19**
255 **patients.**

256 Given the contribution of the neutrophil activation pathway in the clustering of COVID-19
257 patients, we sought neutrophil-activation features that could act as possible reliable markers
258 of disease evolution. We focused on CD177 because: i) it is a neutrophil-specific marker
259 representative of neutrophil activation, ii) it was the most highly differentially expressed gene
260 in patients, and iii) the protein can be measured in the serum, making its use as a marker
261 clinically applicable. Thus, we used an ELISA to quantify CD177 in the serum of 203 COVID-
262 19 patients (115 patients from the French cohort and 88 patients from the Swiss COVID-19
263 cohort that we used as “a confirmatory” cohort, patient characteristics are described in Table

264 2), 21% of whom the measurements were repeated (from 2 to 10 measurements per
265 individual). First, we confirmed the significantly higher median serum protein level in the
266 global cohort of COVID-19 patients (4.5; [2.2-7.4]) relative to that of 16 HDs (2.2 [0.9-4.2]) (P
267 = 0.015, Wilcoxon test) (Figure 6A). Second, we found a robust agreement between CD177
268 gene expression measured by RNA-seq and CD177 protein levels measured by ELISA
269 (intraclass correlation coefficient 0.88), (Figure 6B).

270 Then, we examined the association of clinical characteristics and outcomes with serum
271 CD177 concentration at the time of admission. The serum CD177 concentration was
272 positively associated with the time to symptoms onset ($P = 0.0026$) (Figure 6C) and was
273 higher for patients hospitalized in an ICU (6.0 ng/ml [3.5-9.4] vs 3.3 ng/ml [1.5-5.6], $P <$
274 0.001) (Figure 6D). The association between serum CD177 levels and hospitalization in an
275 ICU was independent of the usual risk factors, such as age, sex, chronic cardiac or
276 pulmonary diseases, or diabetes (multivariable logistic regression, adjusted odds ratio 1.14
277 per unit increase, $P < 0.001$). We observed a trend towards a positive association with the
278 SOFA and SAPS2 risk scores that was not statistically significant ($P = 0.17$ and $P = 0.074$,
279 respectively) (supplementary Figure 5A and B). CD177 levels were not associated with other
280 conditions that contribute to a high risk of severe disease, such as diabetes ($P = 0.632$),
281 chronic cardiac disease ($P = 0.833$), chronic pulmonary disease ($P = 0.478$), or age of the
282 patient ($P = 0.83$) (data not shown).

283 We then examined the dynamics of the CD177 concentration in 172 COVID-19 patients, with
284 longitudinal serum samples, using all available measurements (Figure 6E). At the first
285 measurement, the average concentration of CD177 was not significantly different between
286 the patients who died and those who recovered (5.93 vs 5.06, $P = 0.26$, Wald test). However,
287 CD177 levels decreased significantly in those who recovered (-0.22 ng/mL/day, 95% CI -
288 0.307; -0.139), whereas it was stable in those who died (+0.10 ng/mL/day, 95% CI +0.014;
289 +0.192) and the difference between the two groups was statistically significant (Wald test for
290 interaction, $P = 0.010$). These results show that the stability of CD177 protein levels in severe

291 COVID-19 patients during the course of the disease is a hallmark of a worse prognosis,
292 leading to death.

293 **Discussion**

294 Here, we investigated factors that influence the clinical outcomes of severe COVID-19
295 patients involved in a multicentric French cohort combining standardized whole-blood RNA-
296 Seq analyses, in-depth phenotypic analysis of immune cells, and measurements of a large
297 panel of serum analytes. An integrated and global overview of host markers revealed several
298 pathways associated with the course of COVID-19 disease, with a prominent role for
299 neutrophil activation. This signature included CD177, a specific neutrophil marker of
300 activation, adhesion to the endothelium, and transmigration. The correlation between CD177
301 gene abundance and serum protein levels in the blood of COVID-19 patients underscores
302 the importance of this marker, making the measurement of CD177 levels a reliable approach
303 that is largely accessible in routine care. We also demonstrated that the dynamics of serum
304 CD177 levels is strongly associated with the severity of COVID-19 disease, ICU
305 hospitalization, and survival in an additional cohort of patients.

306 CD177 is a glycosylphosphatidylinositol (GPI)-anchored protein expressed by a variable
307 proportion of human neutrophils. It plays a key role in the regulation of neutrophils by
308 modulating their migration and activation. For example, the CD177 molecule has been
309 identified as the most dysregulated parameter in purified neutrophils from septic shock
310 patients ⁴⁰ and in severe influenza ⁴¹. Clinically, neutrophil chemotaxis, infiltration of
311 endothelial cells, and extravasation into alveolar spaces have been described in lung
312 autopsies from deceased COVID-19 patients ¹⁹. Elevated CD177 mRNA expression has also
313 been described for patients with acute Kawasaki Disease (KD) ⁴² and resistant to IV Ig
314 therapy ^{43,44}, a syndrome that has been described as a possible complication of SARS-CoV-2
315 infection in children ^{45,46}. Our results are also consistent with those obtained using animal
316 models, suggesting an important role for neutrophil activation in the severity of infection with
317 respiratory viruses through their migration towards infected lungs, and in humans infected
318 with influenza ⁴⁷⁻⁴⁹.

319 The neutrophil activation signature is a specific feature of the homing of activated neutrophils
320 toward infected lung tissue in acute lung injury ⁵⁰, followed by the initiation of aggressive
321 responses and the release of neutrophil extracellular traps (NETs), leading to an oxidative
322 burst and the initiation of thrombus formation ⁵¹. Previous studies have reported elevated
323 levels of circulating NETs in COVID-19 disease ⁵². Consistent with this finding and extending
324 these data, we showed the differential expression of NET-related genes ^{41,47,48} (S100A8,
325 S100A9, and S100A12), confirming the recently described elevated expression of
326 calprotectin (heterodimer of S100A8 and A9) in severe COVID-19 patients ¹³. The
327 association of neutrophil activation signature with COVID-19 severity has also been
328 described recently with CD177 gene being one of the most differentially expressed gene in
329 advanced disease ⁵³. Although, it is difficult to formally conclude whether CD177 is a causal
330 factor of disease progression or a consequence of the severity of the disease, our data
331 strongly show that CD177 is a valid hallmark of the physiopathology of COVID-19. This
332 observation suggests that the activation of neutrophils, triggered by the infection, is a
333 fundamental element of the innate response. However, persistent activation of this pathway
334 may constitute, along with other factors (e.g., “cytokine storm”), fatal harm possibly
335 associated with the critical turning point in the clinical trajectory of patients during the second
336 week of the infection.

337 Neutrophil activation was associated with significant changes in the level of gene expression
338 of several pathways, some concordantly associated with disturbances in immune-cell
339 populations and cytokine and inflammatory profiles. We reveal a complex picture of the
340 activation of innate immunity, assessed by significant changes in the expression of several
341 genes involved in interferon signaling and the response to stress and the production of
342 inflammatory/activation markers, with a balance between pro-inflammatory signals
343 (increased expression of IL-1R1, IL-18R1 and its accessory chain IL-18 RAP) and anti-
344 inflammatory cytokines or regulators (increased expression of IL-10, IL-4R, IL-27, IL-1RN)
345 ^{54,55}. The frequency of $\gamma\delta$ T cells, a subpopulation of CD3⁺ T cells that were first described in

346 the lung⁵⁶ and that play critical roles in anti-viral immune responses, tissue healing, and
347 epithelial cell maintenance⁵⁷, was elevated and they expressed an activation marker (CD16)
348 and low levels of the inhibitory receptor NKG2A, suggesting possible killing capacity. In
349 accordance with our observation that Eif2 signaling is significantly inhibited in COVID-19
350 patients, recent studies have shown that coronaviruses encode ISR antagonists, which act
351 as competitive inhibitors of Eif2 signaling^{58,59}. Similarly, the inhibition of mTOR signaling that
352 we found in COVID-19 patients is consistent with the impaired mTOR signaling reported in
353 blood myeloid dendritic cells of COVID-19 patients²¹. Interestingly, we observed a markedly
354 smaller proportion of all DC (pre-DC, pDC, cDC1 and cDC2) and monocyte cell populations,
355 including classical, intermediate, and non-classical subpopulations, in COVID-19 patients
356 than in HDs. Based on these observations, it can be hypothesized that the impairment in
357 IFN- α production observed in severe COVID-19 patients may be the result of both a
358 decrease in the number of pDCs, which are natural IFN-producing cells⁶⁰, and inhibition of
359 mTOR signaling, a regulator of IFN- α production, in these cells⁶¹.

360 We confirmed the previously reported expansion of B-cell populations^{21,22} in COVID-19
361 patients and our results showed that the anti-SARS-CoV-2 B cell repertoire is commonly
362 mobilized. The marked upregulation of IgV gene families included the IgHV1-24 family,
363 described to be specific for COVID-19⁶². The expanded VH4-39 family was also recently
364 reported to be the most highly represented in S-specific SARS-CoV-2 sequences⁶². We also
365 found enrichment of VH3-33, previously described in a set of clonally related anti-SARS-
366 CoV-2 receptor-binding domain antibodies⁶³.

367 Globally, these results show that the defense against SARS-CoV-2 following pathogen
368 recognition triggers a fine-tuned program that not only includes the production of antiviral
369 (Interferon signaling) and pro-inflammatory cytokines but also signals the cessation of the
370 response and a strong disturbance of adaptive immunity.

371 The same pathways (immune and stress responses through Eif2 signaling, neutrophil and
372 Interferon signaling, T- and B-cell receptor responses, and mTOR pathways) contributed to

373 the ability to discriminate between three groups of severe COVID-19 patients in an
374 unsupervised analysis. One limitation of our study was that we did not repeat the RNA-seq
375 analyses in these specific groups of patients. Nonetheless, it is noteworthy that these groups
376 differed significantly by the time from disease onset. These findings provide clues in our
377 understanding of the wide range of profiles previously described for COVID-19 by showing
378 that these patterns may be mainly related to time-dependent changes in the blood during the
379 course of the infection ^{15,64}. For example, the observed lower abundance of IFN signaling
380 genes in the last group of COVID-19 patients may be due to decreased abundance in more
381 advanced disease and/or patients who constitutively present a lower abundance of ISG, as
382 described in previous studies ⁶⁵.

383 Several months after the emergence of this new disease, treatment options for patients with
384 severe disease requiring hospitalization are still limited to corticosteroids, which has emerged
385 as the treatment of choice for critically ill patients ^{66,67}. However, interventions that can be
386 administered early during the course of infection to prevent disease progression and longer-
387 term complications are urgently needed. A major obstacle for the design of “adapted “
388 therapies to the various stages of disease evolution is a lack of markers associated with
389 sudden worsening of the disease of patients with moderate to severe disease and markers to
390 predict improvement. Our results show that the measurement of CD177 during the course of
391 the disease may be helpful in following the response to treatment and revision of the
392 prognosis. In addition, they suggest that therapies aiming to control neutrophil activation and
393 chemotaxis should be considered for the treatment of hospitalized patients.

394 **Materials and Methods**

395 **Subjects**

396 We enrolled a subgroup of COVID19 patients of the prospective French COVID cohort
397 (registered at clinicaltrials.gov NCT04262921) in this immunological study which is part of the
398 cohort main objectives. Ethics approval was given on February 5th by the French Ethics
399 Committee CPP-Ile-de-France VI (ID RCB: 2020-A00256-33). Eligible patients were those
400 who were hospitalized with virologically confirmed COVID-19. Briefly, nasopharyngeal swabs
401 were performed on the day of inclusion for SARS-CoV-2 testing according to WHO or French
402 National Health Agency guidelines. Viral loads were quantified by real-time semi-quantitative
403 reverse transcriptase polymerase chain reactions (RT-PCR) using either the Charité WHO
404 protocol (testing the E gene and RdRp) or the Pasteur institute assay (testing the E gene and
405 two other RdRp targets, IP2 and IP4). The study was conducted with the understanding and
406 the consent of each participant or its surrogate covering the sampling, storage, and use of
407 biological samples. The Swiss cohort was approved by the ethical commission (CER-VD;
408 Swiss ethics protocol ID: 2020-00620) and all subjects provided written informed consent.
409 Blood from healthy donors was collected from the French Blood Donors Organization
410 (Etablissement Français du sang (EFS)) before the COVID-19 outbreak. HD characteristics
411 are shown in Supplementary Table 3.

412 **Quantification of serum analytes**

413 In total, 71 analytes were quantified in heat-inactivated serum samples by multiplex magnetic
414 bead assays or ELISA. Serum samples from five healthy donors were also assayed as
415 controls. The following kits were used according to the manufacturers' recommendations:
416 LXSAHM-2 kits for CD163,ST2,CD14 and LBP (R&D Systems); the LXSAHM-19 kit for IL-21,
417 IL-23, IL-31, EGF, Flt-3 Ligand, Granzyme B, Granzyme A, IL-25, PD-L1/B7-H1, TGF- α ,
418 Aggrecan, 4-1BB/CD137, Fas, FasL,CCL-28, Chemerin, sCD40L, CXCL14, and Midkine
419 (R&D Systems); and the 48-Plex Bio-Plex Pro Human Cytokine screening kit for IL-1 β , IL-
420 1 α , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 / CXCL8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A /

421 CTLA8, Basic FGF (FGF-2), Eotaxin / CCL11, G-CSF, GM-CSF, IFN- γ , IP-10/CXCL10,
422 MCP-1 /CCL2, MIP-1 α / CCL3, MIP-1 β / CCL4, PDGF-BB (PDGF-AB/BB), RANTES/CCL5,
423 TNF- α , VEGF (VEGF-A), IL-1a, IL-2Ra (IL-2R), IL-3, IL-12 (p40), IL-16, IL-18, CTACK /
424 CCL27, GRO-a /CXCL1 (GRO), HGF, IFN- α 2, LIF, MCP-3 / CCL7, M-CSF, MIF,
425 MIG/CXCL9, b-NGF, SCF, SCGF-b ,SDF-1 α ,TNF-b/LTA, and TRAIL (Bio-Rad). The data
426 were acquired using a Bio-Plex 200 system. Extrapolated concentrations were used and the
427 out-of-range values were entered at the highest or lowest extrapolated concentration. Values
428 were standardized for each cytokine across all displayed samples (centered around the
429 observed mean, with variance equal to 1). CD177 quantification was performed on non-
430 inactivated serum samples (diluted 1:2 or 1:10) using a Human CD177 ELISA Kit
431 (ThermoFisher Scientific), according to the manufacturer's instructions.

432 **Cell phenotyping**

433 Immune-cell phenotyping was performed using an LSR Fortessa 4-laser (488, 640, 561, and
434 405 nm) flow cytometer (BD Biosciences) and Diva software version 6.2. FlowJo software
435 version 9.9.6 (Tree Star Inc.) was used for data analysis. CD4⁺ and CD8⁺ T cells were
436 analyzed for CD45RA and CCR7 expression to identify the naive, memory, and effector cell
437 subsets for co-expression of activation (HLA-DR and CD38) and exhaustion/senescence
438 (CD57and PD1) markers. CD19⁺ B-cell subsets were analyzed for the markers CD21 and
439 CD27. ASC (plasmablasts) were identified as CD19⁺ cells expressing CD38 and CD27. We
440 used CD16, CD56, and Ki57 to identify NK-cell subsets. $\gamma\delta$ T cells were identified using an
441 anti-TCR $\gamma\delta$ antibody. HLA-DR, CD33, CD45RA, CD123, CD141, and CD1c were used to
442 identify dendritic cell (DC) subsets, as previously described ⁶⁸

443 **RNA sequencing**

444 Total RNA was purified from whole blood using the Tempus™ Spin RNA Isolation Kit
445 (ThermoFisher Scientific). RNA was quantified using the Quant-iT RiboGreen RNA Assay Kit
446 (Thermo Fisher Scientific) and quality control performed on a Bioanalyzer (Agilent). Globin
447 mRNA was depleted using GlobinClear Kit (Invitrogen) prior to mRNA library preparation with

448 the TruSeq® Stranded mRNA Kit, according to the Illumina protocol. Libraries were
449 sequenced on an Illumina HiSeq 2500 V4 system. Sequencing quality control was performed
450 using Sequence Analysis Viewer (SAV). FastQ files were generated on the Illumina
451 BaseSpace Sequence Hub. Transcript reads were aligned to the hg18 human reference
452 genome using Salmon v0.8.2⁶⁹ and quantified relative to annotation model
453 "hsapiens_gene_ensembl" recovered from the R package biomaRt v2.42.1⁷⁰. Quality control
454 of the alignment was performed via MultiQC v1.4⁶⁹. Finally, counts were normalized as
455 counts per million.

456 **Statistical analysis**

457 Subgroups of COVID-19 patients were identified from unsupervised hierarchical clustering of
458 log2-counts-per-million RNA-seq transcriptomics from whole-blood using the Euclidean
459 distance and Ward's method. Differential expression analysis was carried out using dearseq
460⁷¹ to contribute to the analysis of genes of which the abundance differed across the three
461 COVID-19 patient subgroups and healthy subjects. Once the groups were defined by
462 hierarchical clustering, the analysis of the genes contributing to each group was performed
463 by selecting genes with an absolute fold-change ≥ 1.5 in the comparison of interest for which
464 the difference in expression between HDs and COVID-19 patients was significant ($P \leq 0.05$)
465 (to avoid so called "double dipping" [<https://arxiv.org/abs/2012.02936>]). Pathway analyses of
466 the genes involved in each comparison was performed using Ingenuity Pathway Analysis
467 (IPA®, Qiagen, Redwood City, California, Version 57662101, 2020). For canonical pathway
468 analysis, a Z-score ≥ 2 was defined as the threshold for significant activation, whereas a Z-
469 score ≤ -2 was defined as the threshold for significant inhibition.

470 The integrative analysis of the three types of biological data (RNA-Seq, cell phenotypes,
471 serum analytes) was performed using MOFA+³⁴, a sparse Factor Analysis method. It
472 provides latent variables which are linear combination of the most influential factors for
473 explaining inter-patient variability across the three biological measurement modalities. The
474 first component is presented and called integrative score here. The analyses of factors

475 associated with CD177 protein concentration were performed using non parametric Wilcoxon
476 test or Spearman correlation coefficient when appropriate. To look at the independent
477 association of CD177 with ICU, a logistic regression for the prediction of hospitalization in
478 ICU adjusted for age, sex, chronic cardiac disease, chronic pulmonary disease, diabetes was
479 fitted. The analysis of repeated measurements of CD177 over time was done by using a
480 linear mixed effect model adjusted for time from hospitalization and an interaction with
481 survival outcome (death or recovery). The model included a random intercept and a random
482 slope with an unstructured matrix for variance parameters. Predictions of marginal
483 trajectories were performed. All analyses, if not stated otherwise, were performed using R
484 software version 3.6.3 (R Core Team (2020)). R: A language and environment for statistical
485 computing. R Foundation for Statistical Computing, Vienna, Austria. URL: [https://www.R-](https://www.R-project.org/)
486 [project.org/](https://www.R-project.org/)

487 **Data availability**

488 RNA sequencing data that support the findings of this study will be deposited in the Gene
489 Expression Omnibus (GEO) repository. Other data will be provided as Source data files.

490

491 **Acknowledgments**

492 We thank the patients who donated their blood. We thank F. Mentre, S. Tubiana, the French
493 COVID cohort, and REACTing (REsearch & ACtion emergING infectious diseases) for cohort
494 management. We thank the scientific advisory board of the French COVID-19 cohort
495 composed of Dominique Costagliola, Astrid Vabret, Hervé Raoul, and Laurence Weiss. We
496 thank Romain Levy for fruitful discussions.

497 **Author Contributions**

498 YL and AW conceived and designed the study. MC, JFT, YY, LB, DB, GP, and MP
499 participated in sample and clinical data collection. EF, MDe, MS, CLe, and PT performed the
500 experiments. MD, MG, BH, and CLe analyzed the data. YL, RT, AW, HH, MS, BJH, and CL
501 analyzed and interpreted the data. YL, RT, AW, and HH drafted the first version and wrote
502 the final version of the manuscript. All authors approved the final version.

503 **Conflict of interest statement**

504 None of the authors has any conflict of interest to declare.

505 **Funding statement**

506 This work was supported by INSERM and the Investissements d’Avenir program, Vaccine
507 Research Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01. The
508 French COVID Cohort is funded through the Ministry of Health and Social Affairs and
509 Ministry of Higher Education and Research dedicated COVID19 fund and PHRC n°20-0424
510 and the REACTing consortium. Funding sources were not involved in the study design, data
511 acquisition, data analysis, data interpretation, or writing of the manuscript.

512

513

514

515

516 References

- 517 1. Coronaviridae Study Group of the International Committee on Taxonomy of, V. The
518 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
519 nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-544 (2020).
- 520 2. Phelan, A.L., Katz, R. & Gostin, L.O. The Novel Coronavirus Originating in Wuhan,
521 China: Challenges for Global Health Governance. *JAMA* (2020).
- 522 3. Wu, Z.Y. & McGoogan, J.M. Characteristics of and Important Lessons From the
523 Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72
524 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama-J Am*
525 *Med Assoc* **323**, 1239-1242 (2020).
- 526 4. Blanco-Melo, D., *et al.* Imbalanced Host Response to SARS-CoV-2 Drives
527 Development of COVID-19. *Cell* **181**, 1036-1045 e1039 (2020).
- 528 5. Chen, G., *et al.* Clinical and immunological features of severe and moderate
529 coronavirus disease 2019. *J Clin Invest* (2020).
- 530 6. Kuri-Cervantes, L., *et al.* Immunologic perturbations in severe COVID-19/SARS-CoV-
531 2 infection. *bioRxiv* (2020).
- 532 7. Mehta, P., *et al.* COVID-19: consider cytokine storm syndromes and
533 immunosuppression. *The Lancet* **395**, 1033-1034 (2020).
- 534 8. Qin, C., *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan,
535 China. *Clin Infect Dis* (2020).
- 536 9. Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in
537 severe COVID-19 patients. *Science* **369**, 718-724 (2020).
- 538 10. Mathew, D., *et al.* Deep immune profiling of COVID-19 patients reveals distinct
539 immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).
- 540 11. Wilk, A.J., *et al.* A single-cell atlas of the peripheral immune response in patients with
541 severe COVID-19. *Nat Med* **26**, 1070-1076 (2020).

- 542 12. Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A. & Ozben, T. Biomarkers associated with
543 COVID-19 disease progression. *Critical Reviews in Clinical Laboratory Sciences* **57**,
544 389-399 (2020).
- 545 13. Silvin, A., *et al.* Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
546 Severe from Mild COVID-19. *Cell* (2020).
- 547 14. Lucas, C., *et al.* Longitudinal analyses reveal immunological misfiring in severe COVID-
548 19. *Nature* **584**, 463-469 (2020).
- 549 15. Ong, E.Z., *et al.* A Dynamic Immune Response Shapes COVID-19 Progression. *Cell*
550 *Host Microbe* **27**, 879-882 e872 (2020).
- 551 16. Giamarellos-Bourboulis, E.J., *et al.* Complex Immune Dysregulation in COVID-19
552 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-1000 e1003
553 (2020).
- 554 17. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in
555 Wuhan, China. *Lancet* **395**, 497-506 (2020).
- 556 18. Zhou, Z., *et al.* Heightened Innate Immune Responses in the Respiratory Tract of
557 COVID-19 Patients. *Cell Host Microbe* **27**, 883-890 e882 (2020).
- 558 19. Fu, J., *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-
559 dimer in COVID-19: A retrospective study in Suzhou China. *Thrombosis Research* **192**,
560 3-8 (2020).
- 561 20. Chen, N., *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
562 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513
563 (2020).
- 564 21. Arunachalam, P.S., *et al.* Systems biological assessment of immunity to mild versus
565 severe COVID-19 infection in humans. *Science* (2020).
- 566 22. Bouadma, L., *et al.* Immune Alterations in a Patient with SARS-CoV-2-Related Acute
567 Respiratory Distress Syndrome. *J Clin Immunol* (2020).

- 568 23. Yazdanpanah, Y. Impact on disease mortality of clinical, biological, and virological
569 characteristics at hospital admission and overtime in COVID-19 patients. *Journal of*
570 *Medical Virology* (2020).
- 571 24. De Biasi, S., *et al.* Marked T cell activation, senescence, exhaustion and skewing
572 towards TH17 in patients with COVID-19 pneumonia. *Nat Commun* **11**, 3434 (2020).
- 573 25. Xu, B., *et al.* Suppressed T cell-mediated immunity in patients with COVID-19: A clinical
574 retrospective study in Wuhan, China. *J Infect* **81**, e51-e60 (2020).
- 575 26. Cai, Y.Q., *et al.* Multiple pathophysiological roles of midkine in human disease.
576 *Cytokine* **135**, 155242 (2020).
- 577 27. Bayat, B., *et al.* Neutrophil Transmigration Mediated by the Neutrophil-Specific Antigen
578 CD177 Is Influenced by the Endothelial S536N Dimorphism of Platelet Endothelial Cell
579 Adhesion Molecule-1. *The Journal of Immunology* **184**, 3889-3896 (2010).
- 580 28. Theilgaard-Monch, K. Haptoglobin is synthesized during granulocyte differentiation,
581 stored in specific granules, and released by neutrophils in response to activation. *Blood*
582 **108**, 353-361 (2006).
- 583 29. Roth, J., Vogl, T., Sorg, C. & Sunderkötter, C. Phagocyte-specific S100 proteins: a
584 novel group of proinflammatory molecules. *Trends in Immunology* **24**, 155-158 (2003).
- 585 30. Levin, D. & London, I.M. Regulation of protein synthesis: activation by double-stranded
586 RNA of a protein kinase that phosphorylates eukaryotic initiation factor 2. *Proc Natl*
587 *Acad Sci U S A* **75**, 1121-1125 (1978).
- 588 31. Pakos-Zebrucka, K., *et al.* The integrated stress response. *EMBO Rep* **17**, 1374-1395
589 (2016).
- 590 32. Le Gall, J.R. A new Simplified Acute Physiology Score (SAPS II) based on a
591 European/North American multicenter study. *JAMA: The Journal of the American*
592 *Medical Association* **270**, 2957-2963 (1993).
- 593 33. Vincent, J.-L., *et al.* Use of the SOFA score to assess the incidence of organ
594 dysfunction/failure in intensive care units. *Critical Care Medicine* **26**, 1793-1800 (1998).

- 595 34. Argelaguet, R., *et al.* Multi-omics profiling of mouse gastrulation at single-cell
596 resolution. *Nature* **576**, 487-+ (2019).
- 597 35. Zhi, Y., *et al.* Clinical significance of sCD163 and its possible role in asthma (Review).
598 *Mol Med Rep* **15**, 2931-2939 (2017).
- 599 36. Buechler, C., Eisinger, K. & Krautbauer, S. Diagnostic and prognostic potential of the
600 macrophage specific receptor CD163 in inflammatory diseases. *Inflamm Allergy Drug*
601 *Targets* **12**, 391-402 (2013).
- 602 37. Boyd, J.H., *et al.* Increased Plasma PCSK9 Levels Are Associated with Reduced
603 Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. *J*
604 *Innate Immun* **8**, 211-220 (2016).
- 605 38. Dwivedi, D.J., *et al.* Differential Expression of PCSK9 Modulates Infection,
606 Inflammation, and Coagulation in a Murine Model of Sepsis. *Shock* **46**, 672-680 (2016).
- 607 39. Gan, E.S., *et al.* Dengue virus induces PCSK9 expression to alter antiviral responses
608 and disease outcomes. *J Clin Invest* (2020).
- 609 40. Demaret, J., *et al.* Identification of CD177 as the most dysregulated parameter in a
610 microarray study of purified neutrophils from septic shock patients. *Immunology Letters*
611 **178**, 122-130 (2016).
- 612 41. Tang, B.M., *et al.* Neutrophils-related host factors associated with severe disease and
613 fatality in patients with influenza infection. *Nat Commun* **10**, 3422 (2019).
- 614 42. Huang, W.D., *et al.* Association between maternal age and outcomes in Kawasaki
615 disease patients. *Pediatr Rheumatol* **17**(2019).
- 616 43. Jing, Y., *et al.* Neutrophil extracellular trap from Kawasaki disease alter the biologic
617 responses of PBMC. *Biosci Rep* (2020).
- 618 44. Ko, T.M., *et al.* Genome-wide transcriptome analysis to further understand neutrophil
619 activation and lncRNA transcript profiles in Kawasaki disease. *Sci Rep* **9**, 328 (2019).
- 620 45. Toubiana, J., *et al.* Kawasaki-like multisystem inflammatory syndrome in children
621 during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*
622 **369**, m2094 (2020).

- 623 46. Viner, R.M. & Whittaker, E. Kawasaki-like disease: emerging complication during the
624 COVID-19 pandemic. *Lancet* **395**, 1741-1743 (2020).
- 625 47. Brandes, M., Klauschen, F., Kuchen, S. & Germain, R.N. A systems analysis identifies
626 a feedforward inflammatory circuit leading to lethal influenza infection. *Cell* **154**, 197-
627 212 (2013).
- 628 48. Narasaraju, T., *et al.* Excessive neutrophils and neutrophil extracellular traps contribute
629 to acute lung injury of influenza pneumonitis. *Am J Pathol* **179**, 199-210 (2011).
- 630 49. Zaas, A.K., *et al.* Gene Expression Signatures Diagnose Influenza and Other
631 Symptomatic Respiratory Viral Infections in Humans. *Cell Host & Microbe* **6**, 207-217
632 (2009).
- 633 50. Juss, J.K., *et al.* Acute Respiratory Distress Syndrome Neutrophils Have a Distinct
634 Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. *Am J Resp Crit*
635 *Care* **194**, 961-973 (2016).
- 636 51. Darbousset, R., *et al.* Tissue factor–positive neutrophils bind to injured endothelial wall
637 and initiate thrombus formation. *Blood* **120**, 2133-2143 (2012).
- 638 52. Barnes, B.J., *et al.* Targeting potential drivers of COVID-19: Neutrophil extracellular
639 traps. *Journal of Experimental Medicine* **217**(2020).
- 640 53. Aschenbrenner, A.C., *et al.* (2020).
- 641 54. Kim, S.H., Han, S.Y., Azam, T., Yoon, D.Y. & Dinarello, C.A. Interleukin-32: a cytokine
642 and inducer of TNFalpha. *Immunity* **22**, 131-142 (2005).
- 643 55. Migliorini, P., Italiani, P., Pratesi, F., Puxeddu, I. & Boraschi, D. The IL-1 family
644 cytokines and receptors in autoimmune diseases. *Autoimmun Rev* **19**, 102617 (2020).
- 645 56. Augustin, A., Kubo, R.T. & Sim, G.K. Resident pulmonary lymphocytes expressing the
646 gamma/delta T-cell receptor. *Nature* **340**, 239-241 (1989).
- 647 57. Cheng, M. & Hu, S. Lung-resident gammadelta T cells and their roles in lung diseases.
648 *Immunology* **151**, 375-384 (2017).
- 649 58. Rabouw, H.H., *et al.* Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits
650 PKR-Mediated Antiviral Stress Responses. *PLoS Pathog* **12**, e1005982 (2016).

- 651 59. Rabouw, H.H., *et al.* Inhibition of the integrated stress response by viral proteins that
652 block p-eIF2-eIF2B association. *Nat Microbiol* (2020).
- 653 60. Ali, S., *et al.* Sources of Type I Interferons in Infectious Immunity: Plasmacytoid
654 Dendritic Cells Not Always in the Driver's Seat. *Frontiers in Immunology* **10**(2019).
- 655 61. Kaur, S., *et al.* Regulatory effects of mTORC2 complexes in type I IFN signaling and in
656 the generation of IFN responses. *Proceedings of the National Academy of Sciences*
657 **109**, 7723-7728 (2012).
- 658 62. Brouwer, P.J.M., *et al.* Potent neutralizing antibodies from COVID-19 patients define
659 multiple targets of vulnerability. *Science* **369**, 643-650 (2020).
- 660 63. Barnes, C.O., *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike
661 Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842
662 e816 (2020).
- 663 64. Laing, A.G., *et al.* A dynamic COVID-19 immune signature includes associations with
664 poor prognosis. *Nat Med* (2020).
- 665 65. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-threatening
666 COVID-19. *Science* **370**, eabd4585 (2020).
- 667 66. Prescott, H.C. & Rice, T.W. Corticosteroids in COVID-19 ARDS. *Jama* **324**, 1292
668 (2020).
- 669 67. Sterne, J.A.C., *et al.* Association Between Administration of Systemic Corticosteroids
670 and Mortality Among Critically Ill Patients With COVID-19. *Jama* **324**, 1330 (2020).
- 671 68. See, P., *et al.* Mapping the human DC lineage through the integration of high-
672 dimensional techniques. *Science* **356**(2017).
- 673 69. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast
674 and bias-aware quantification of transcript expression. *Nature Methods* **14**, 417-419
675 (2017).
- 676 70. Durinck, S., Spellman, P.T., Birney, E. & Huber, W. Mapping identifiers for the
677 integration of genomic datasets with the R/Bioconductor package biomaRt. *Nature*
678 *Protocols* **4**, 1184-1191 (2009).

679 71. Gauthier, M., Agniel, D., Thiébaud, R. & Hejblum, B.P. dearseq: a variance component
680 score test for RNA-Seq differential analysis that effectively controls the false discovery
681 rate. (2019).

682

683

684 **Figure legends**

685 **Figure 1. Frequency of immune-cell subsets between HD (n = 18) and COVID-19**
686 **patients (n = 50). A** Frequency of total CD3 T cells, CD4 and CD8 T-cell subsets, and
687 activated CD38⁺HLADR⁺ CD8 T cells. **B** Frequency of B-cell subsets (CD21⁺CD27⁺: resting
688 memory, CD21⁻CD27⁺: activated memory, CD21⁻CD27⁻: exhausted) and plasmablasts
689 (CD38⁺⁺CD27⁺) gated on CD19⁺ B cells. **C** Frequency of NK-cell subsets (gated on CD3⁻
690 CD14⁻) CD56^{Bright}: CD56⁺⁺CD16⁺, CD56^{dim}: CD56⁺CD16⁺⁺CD57^{+/-}, differentiated Ki67⁺ NK
691 cells (gated on CD56^{Bright} or CD56^{dim}CD57⁻ NK cells) and differentiated Ki67⁺ NKT cells
692 (gated on CD3⁺CD56⁺ cells). **D** Monocyte subsets (gated on CD3⁻CD56⁻) (classical
693 monocytes: CD14⁺CD16⁻, intermediate monocytes: CD16⁺CD14⁺, non-classical monocytes:
694 CD14⁻CD16⁺). **E** Frequency of $\gamma\delta$ T cells (gated on CD3⁺ T cells) and CD16 and NKG2A
695 expression (gated on $\gamma\delta$ CD3 T cells). **F** Frequency of DC subsets (gated on HLADR⁺Lin⁻)
696 (pDC: CD45RA⁺CD33⁻CD123⁺, pre-DC: CD123⁺CD45RA⁺, cDC1: CD33⁺CD123⁻
697 CD141⁺CD1c^{low}, cDC2: CD33⁺CD123⁻CD14⁺CD1c⁺) detected by flow cytometry in PBMCs
698 from n = 50 COVID19 patients and n = 18 HDs. The differences between the two groups
699 were evaluated using Wilcoxon rank sum statistical tests. The lower and upper boundaries of
700 the box represent the 25% and 75% percentiles, the whiskers extend to the most extreme
701 data point that is no more than 1.5 times the interquartile range away from the box. Median
702 values (horizontal line in the boxplot) are shown.

703 **Figure 2. Heatmap of analyte abundance in serum.** The colors represent standardized
704 expression values centered around the mean, with variance equal to 1. HD: healthy donors
705 (n = 5), COVID: COVID19 patients (n = 33). Each column represents a subject. Each line
706 represents an analyte.

707 **Figure 3. Whole blood gene expression in COVID-19 patients and HDs. A.** Volcano plot
708 showing differentially expressed genes (DEG) according to the log₂ fold change (log₂ FC)
709 and Benjamini-Hochberg False Discovery Rate (FDR) with thresholds at absolute log₂ FC \geq
710 log₂(1.5) and FDR \leq 0.05. **B** Main top DEG related to neutrophils. **C** and **D** Main DEG related

711 to IFN and interleukin responses, respectively. **E** Main TCRV T-cell repertoire DEG **F** Main
712 B-cell IGHV repertoire DEG. Red symbols represent overabundant genes in COVID-19
713 relative to HD, green symbols represent underabundant genes.

714 **Figure 4. Heatmap of standardized gene expression.** The colors represent standardized
715 expression values centered around 0, with variance equal to 1. Each column represents a
716 subject. This heatmap was built by unsupervised hierarchical clustering of log₂-counts-per-
717 million RNA-seq transcriptomic data from whole blood (29,302 genes) and subjects (n = 54)
718 using the Euclidean distance and Ward's method. Seven blocks are highlighted according to
719 the features of gene expression across the groups of individuals. Enrichment (number and %
720 of genes of a given pathway selected in the block) of pathways of interest are shown for each
721 block.

722 **Figure 5. Integrative analysis.** Integrative analysis of the data of RNA-seq (29,302 genes)
723 from 44 COVID-19 patients, cell phenotype (52 types) from 45 COVID-19 patients, and
724 serum analytes (71 analytes) from 33 COVID-19 patients using a sparse principal component
725 analysis approach, MOFA v2. **A** Integrative score according to the patient groups defined by
726 the hierarchical clustering of the RNA-seq data. Top 10 marker contributions (according to
727 the weight from -1 to 1) of the cell phenotypes (**B**), serum analytes (**C**), and RNA-seq (**D**).
728 The integrative score corresponds to the first factor of the analysis and allows the ordering of
729 individuals along an axis centered at 0. Individuals with an opposite sign for the factor
730 therefore have opposite characteristics.

731 **Figure 6: Distribution of the CD177 marker and association with clinical outcomes of**
732 **COVID-19 patients. A** Measurement of CD177 (ng/ml). HD: Healthy donors (n = 16),
733 COVID-19 patients (n = 203). The difference between the two groups was evaluated using
734 Wilcoxon rank sum statistical tests. The median values (horizontal line in the boxplot) are
735 shown. The lower and upper boundaries of the box represent the 25% and 75% percentiles.
736 **B** Correlation between normalized CD177 values of gene expression measured by RNA-seq
737 and CD177 protein by ELISA (ng/ml) from 36 COVID-19 patients. The blue line represents

738 the linear regression line and the grey area the 95% prediction confidence interval. **C**

739 Association between CD177 serum concentration and time from symptoms onset (n = 192).

740 This association was tested using Spearman correlation tests. The blue line represents the

741 linear regression line and the grey area the 95% confidence interval. **D** Measurement of

742 CD177 serum concentration in patients hospitalized in an intensive care unit (ICU) or not (n =

743 196). Wilcoxon rank tests were used. The median values (horizontal line in the boxplot) are

744 shown. The lower and upper boundaries of the box represent the 25% and 75% percentiles.

745 **E.** Change of CD177 concentration over time according to the occurrence of death for 172

746 COVID-19 patients and a total of 248 measurements. Predictions were calculated using a

747 mixed effect models for longitudinal data.

748

749

750

751

752

753

754 **Table 1. Patient characteristics of the French COVID cohort (n=61)**

		No.
Demographic characteristics		
Age - Median (IQR) - years	61	60 (50 - 69)
Male sex – No./total No. (%)	61	49/61 (80)
ICU or transfer to ICU or death – No./total No. (%)	61	53/61 (87)
Outcome – No./total No. (%)	61	
Death		21/61 (34)
Discharge alive		40/61 (66)
Median interval from first symptoms on admission (IQR)-days	61	11 (7 - 14)
Comorbidities – No./total No. (%)		
Any	61	14/61 (23)
Chronic cardiac disease	61	9/61 (15)
Hypertension	61	22/61 (36)
Chronic pulmonary disease	61	5/61 (8)
Asthma	61	4/61 (7)
Chronic kidney disease	61	6/61 (10)
Chronic neurological disorder	61	2/61 (3)
Obesity	60	23/60 (38)
Diabetes	61	12/61 (20)
Smoking History – No./total No. (%)		
Smoking	61	5/61 (8)
Laboratory findings on admission - Median (IQR)		
Hemoglobin - g/dL	57	13 (11 - 14)
WBC count - x10 ⁹ /L	57	6 (5 - 9)
Platelet count - x10 ⁹ /L	57	189 (143 - 270)
C-reactive protein (CRP) - mg/L	57	120 (66 - 195)
Blood Urea Nitrogen (urea) - mmol/L	57	7 (5 - 12)
Symptoms on admission - No./total No. (%)		
Fever	59	51/59 (86)
Cough	57	40/57 (70)
Sore throat	56	4/56 (7)

Wheezing	54	6/54 (11)
Myalgia	56	21/56 (38)
Arthralgia	55	9/55 (16)
Fatigue	57	27/57 (47)
Dyspnea	57	46/57 (81)
Headache	57	11/57 (19)
Altered consciousness	56	3/56 (5)
Abdominal pain	53	8/53 (15)
Vomiting / nausea	56	10/56 (18)
Diarrhea	56	11/56 (20)

Clinical characteristics on admission -

Median (IQR)

SOFA score (ICU patients)	34	6 (4 - 8)
SAPS2 (ICU patients)	36	32 (27 - 53)
Heart rate - beats per minute	61	87 (76 - 104)
Respiratory rate - breaths per minute	55	24 (20 - 32)
Systolic blood pressure - mmHg	60	130 (109 - 145)
Diastolic blood pressure - mmHg	60	77 (70 - 87)
Oxygen saturation - percent	61	96 (91 - 98)
Oxygen saturation on – No./total No. (%)	56	
Room air		17/56 (30)
Oxygen therapy		39/56 (70)


Treatments – No./total No. (%)




Antiviral	60	40/60 (66)
Antibiotic	60	46/60 (77)
Corticosteroids	60	33/60 (55)
Antifungal	60	9/60 (15)
Hydroxychloroquine	59	8/59 (14)

755 **Table 2. Characteristics of patients involved in the CD177 analysis**


756

	No.	French cohort (n = 115)	Swiss cohort (n = 88)
Demographic characteristics			
Age - Median (IQR) - years	200	62 (54-72)	63 (57-74)
Male sex - No./total No. (%)	201	82/113 (73)	56/88 (64)
ICU or transfer to ICU or death - No. /total No. (%)	200	61/112 (54)	40/88 (45)
Outcome - No. /total No. (%)	173		
Death		32/107 (30)	8/66 (12)
Discharge alive		75/107 (70)	58/66 (88)
Median interval from first symptoms on admission (IQT)	192	13 (9-18)	12 (9-17)
Comorbidities - No./total No. (%)			
Chronic cardiac disease	197	22/109 (20)	25/88 (28)
Chronic pulmonary disease	197	14/109 (13)	9/88 (10)
Diabetes	197	23/109 (21)	26/88 (30)
Laboratory findings on admission - Median (IQR)			
C-reactive protein (CRP) - mg/L	34	122 (62-196)	
Lactate dehydrogenase (LDH) UI/L	31	466 (337-533)	
Clinical characteristics on admission - Median (IQR)			
Score SOFA	41	4 (2-7)	
Score SAPS2	40	32 (27-49)	




D**E****F**


761 Figure 2



762



777 Figure 4



778


779

780


781

782


A




B



C



D



785 Figure 6

